Article

Ovarian reserve and oocyte maturity in women with malignancy undergoing in vitro maturation treatment.

Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada.
Fertility and sterility (Impact Factor: 3.97). 01/2011; 95(5):1621-3. DOI: 10.1016/j.fertnstert.2010.12.041
Source: PubMed

ABSTRACT To evaluate ovarian reserve and oocyte maturity in women with malignancy.
A case-control study.
University teaching hospital.
We evaluated all women with malignancy who underwent in vitro maturation treatment for fertility preservation from the year 2003 to 2009. The results were compared with those of an age-matched infertile control group.
In vitro maturation treatment.
Ovarian reserve and oocyte maturity.
Women with malignancy of the breast (n = 87), hematologic malignancy (n = 16), gynecologic or abdominal malignancy (n = 9), and other malignancies (n = 16) were compared with infertile control women (n = 79). The age was similar in all groups except in women with hematologic malignancy where they were younger than the control group (24.9 ± 1.1 years vs. 30.8 ± 0.4 years, confidence interval 4.0-9.5). Baseline FSH in this group was also lower than in the control group. Women with breast cancer had a lower number of retrieved oocytes than the control group (95% confidence interval 0-5). There were no significant differences in antral follicle count, percentage of mature oocytes on collection day, and percentage of metaphase II oocytes matured in vitro among all groups of women.
Women with breast cancer have fewer numbers of retrieved oocytes than infertile controls. Ovarian reserve and oocyte maturity in other types of malignancy are similar to those in the control group.

0 Bookmarks
 · 
70 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper proposes a hot-carrier stressed high frequency noise model for MOSFETs. By analytical method, a new fresh and post-stress high-frequency MOSFET noise model is developed, this model incorporates the effects of gate resistance, gate-induced current noise and nonlocal channel carrier heating, it can be used to calculate the minimum noise figure F<sub>run</sub>, optimized source admittance Y<sub>opt</sub>, and equivalent noise resistance R<sub>n</sub> and admittance G<sub>i</sub>. Within this model, the effects of hot-carrier stress induced interface states on the high-frequency noise performance can be evaluated. Modeling shows agreement with the measured data.
    Solid-State and Integrated Circuits Technology, 2004. Proceedings. 7th International Conference on; 11/2004
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The need for practice guidelines for fertility preservation in young women with hematological malignancies has been increased. To develop recommendations, publications relevant to fertility preservation and hematological cancers were identified through a PubMed database search and reviewed systematically, focusing on the effects of oncological treatments on fertility as well as on the efficacy, feasibility and risks of existing fertility preservation methods.
    Journal of Assisted Reproduction and Genetics 05/2012; 29(6):479-87. · 1.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE OF REVIEW: To delineate the current trends in the clinical application of oocyte cryopreservation. RECENT FINDINGS: Although the first live birth from oocyte cryopreservation was reported approximately three decades ago, significant improvement in the clinical application of oocyte cryopreservation took place only over the past decade. On the basis of the available evidence suggesting that success rates with donor oocyte vitrification are similar to that of IVF with fresh donor oocytes, the American Society of Reproductive Medicine has recently stated that oocyte cryopreservation should no longer be considered experimental for medical indications, outlying elective oocyte cryopreservation. Meanwhile, a few surveys on the attitudes toward oocyte cryopreservation revealed that elective use for the postponement of fertility is currently the most common indication for oocyte cryopreservation. Most recently, a randomized controlled trial revealed important evidence on the safety of nondonor oocyte cryopreservation, and confirmed that the clinical success of vitrification is comparable to that of IVF with fresh oocytes. SUMMARY: The evidence suggesting similar IVF success rates with both donor and nondonor cryopreserved oocytes compared with fresh oocytes will increase the utilization of elective oocyte cryopreservation. Appropriate counseling of women for oocyte cryopreservation requires the establishment of age-based clinical success rates with cryopreserved oocytes for various indications.
    Current opinion in obstetrics & gynecology 04/2013; · 2.49 Impact Factor